Skip to main content
SSO 2024 Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Recorded for On-Demand Viewing
Recorded for On-Demand Viewing
Back

E. Shelley Hwang, MD, MPH

Mary and Deryl Hart Distinguished Professor of Surgery
Duke University School of Medicine
Durham, North Carolina, United States

Dr. Hwang has been a faculty member of Duke University since 2011, serving as the Vice Chair of Research for the Department of Surgery since 2015 and the Mary and Deryl Hart Professor of Surgery and Director of the Breast Oncology Program at the Duke Cancer Institute since 2022.

Dr. Hwang’s research focuses on breast cancer prevention; identifying less invasive treatments for early stage breast cancers including previnvasive cancer (DCIS); and understanding the genetic and stromal determinants of cancer progression. She also studies novel immune approaches to breast cancer treatment.

Dr. Hwang is active on the national stage, serving as a member of the National Cancer Institute Breast Cancer Steering Committee, National Comprehensive Cancer Network (NCCN) Guidelines Committees, and Co-Chair of the Human Tumor Atlas Network. In addition, she has participated in national and international panels and consortia to establish guidelines for DCIS, node-positive breast cancer, neoadjuvant therapy, and clinical trials endpoints for breast cancer. In 2016, she was honored as a Time 100 recipient for her innovative work in early stage breast cancer.

Dr. Hwang conducts clinical research and runs a basic science research lab focused on predictors of invasion in breast precancers. Her research is funded by grants from the National Institutes of Health, the National Cancer Institute, the Department of Defense, the Patient Centered Outcomes Research Institute (PCORI), the Breast Cancer Research Fund and CRUK. She is principal investigator of the Pre-Cancer Atlas Research Centers (U2C) project, and the PCORI COMET trial, a multicenter study of active surveillance versus usual care for low-risk DCIS being conducted at over 80 study sites.

Presentation(s):